TheralinkTheralink

  • Theralink
    • The Theralink platform
    • The Theralink Assay
    • Request RPPA Analyte List
    • RPPA Clinical Publications
    • RPPA Research Publications
    • RPPA Technical Publications
  • About
    • Overview
    • Oncologists
    • Mission Statement
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
    • Career
  • News & Media
    • Press Releases
    • Media Coverage
    • Theralink Blog
  • Biopharmas
    • Overview
    • Explore Technology
    • Explore Targets
    • Explore Pathways
    • Request Pathway Quote
    • FAQ
  • INVESTOR RELATIONS
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Information
    • Stock Information
    • Investor Resources
      • FAQ
      • Contact Us
    • Corporate Governance
      • Management Team
      • Medical Advisory Board
      • Scientific Advisory Board
      • Board of Directors
  • Contact

H.C. Wainwright 22nd Annual Global Investment Conference

Theralink   →  Media Room   →  Events   →  H.C. Wainwright 22nd Annual Global Investment Conference
10
Sep
Date September 10, 2020
Categories Events

H.C. Wainwright 22nd Annual Global Investment Conference

Mick Ruxin, M.D., President and CEO of Theralink, will present at the H.C. Wainwright 22nd Annual Global Investment Conference to be held virtually on Wednesday,

September 16, 2020. 12:30 p.m. ET.

To attend, please register here: https://rb.gy/oifxe9 

Author support@madxde.com

Recent Posts

  • Theralink® Technologies Achieves Major Milestone: California Clinical and Public Health License for its Golden, CO Laboratory
  • Theralink® Technologies Moves Closer Toward Changing the Standard of Care for All Women Newly Diagnosed with HER2+ Breast Cancer
  • Theralink® Technologies Announces Milestone Event–The Commencement of Testing on its First Patients
  • Theralink® Technologies Issues Letter to Shareholders
  • Theralink® Technologies Announces Partnership with Perthera to Facilitate and Accelerate Access to its Unique Phosphoprotein and Drug Target Activation Testing in the U.S.
Theralink Technologies intends to be a market leader in precision medicine for more effective cancer treatments

Menu

  • About
  • Investors
  • Contact
  • Privacy Policy

OUR SERVICES

  • Biopharmas
  • Oncologists
  • Media Room

Press Releases

  • Theralink® Technologies Achieves Major Milestone: California Clinical and Public Health License for its Golden, CO Laboratory
  • Theralink® Technologies Moves Closer Toward Changing the Standard of Care for All Women Newly Diagnosed with HER2+ Breast Cancer
  • Theralink® Technologies Announces Milestone Event–The Commencement of Testing on its First Patients
Copyright © 2020 Theralink. All rights reserved.